PCYNOTCPharmaceutical PreparationsFiscal year ends June 30
PROCYON CORP
Financials through Q4 FY2024, quarter ended Jun 30, 2024Last filing: 10-K on Oct 25, 2024
$0.18−0.09 (-31.48%)
Close on Oct 19, 2026
- Market cap
- $1.51M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.0620 (+50.41%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
PROCYON CORP grew revenue 6.4% to $4.98M over the twelve months to Jun 30, 2024. Free cash flow was -$125.16K.
Revenue
$4.98M
+6.4% vs. a year earlier
Operating income
-$231.71K
TTM Q4 2024
Free cash flow
-$125.16K
TTM Q4 2024
EPS, diluted
-$0.04
TTM Q4 2024
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2024
Valuation
- Market cap
- $1.51M
- P/E ratio
- –
- Price to sales
- 0.30
- Price to book
- 0.66
- Dividend yield
- –
- Free cash flow yield
- -8.29%
Fundamentals
- Revenue
- $4.98M
- Net income
- -$341.14K
- EPS, diluted
- -$0.04
- Free cash flow
- -$125.16K
- Book value per share
- $0.28
- Diluted shares
- 8M
Fifteen years at a glance
Fiscal years 2010 to 2024, USD
Revenue
$4.98M+6.4% YoY
Gross profit
$3.89M+9.0% YoY
Operating income
-$231.71K
Net income
-$341.14K
EPS, diluted
-$0.04
Free cash flow
-$125.16K
Reported period